Phase 1 N=11 The Behavioral Effects of Opioids and Alcohol
Opioid Use · Alcohol Drinking
Primary: Peak Subject-Rated Outcome: Visual Analog Scale (VAS) Drug Liking — 12.9; 47.1; 49.9; 54.8 score on a scale
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 1 N=64 Study to Assess PDM608 in Healthy Adult Subjects
Parkinson Disease
Primary: Number of Participants With Adverse Events — 0; 0; 0; 0 Participants
Phase 1 N=62 Pectointercostal Fascial Plane Block (PIFB) Alone Versus PIFB With Rectus Sheath Block (RSB) in Cardiac Surgery
Coronary Artery Disease · Postoperative Pain · Respiratory Failure
Primary: Pain Scores at Rest Within the First 24 Hours After Extubation — 79.25; 102 Numeric rating score * hours.
Phase 1 N=16 A Study of Belimumab in Chinese Pediatric Participants With Systemic Lupus Erythematosus
Systemic Lupus Erythematosus
Primary: Area Under the Curve at Steady-state to the End of the Dosing Period (AUCss,0-tau) of Belimumab for Participants Weighing Greater Than or Equal to (>=) 50 Kilograms (kg)…
Phase 1 N=46 Clinical Trial to Evaluate the Safety and Immunogenicity of Synthetic DNAs Encoding NP-GT8 and IL-12, With or Without a TLR-agonist-Adjuvanted HIV Env Trimer 4571 Boost, in Adults Without HIV
HIV Infections
Primary: Number of Participants Reporting Local Solicited Adverse Events Signs and Symptoms: Pain and/or Tenderness — 3; 9; 4; 6 Participants
Phase 1 N=6 A Trial Evaluating TG4050 in Ovarian Carcinoma.
Ovarian Carcinoma · Fallopian Tube Cancer · Peritoneal Carcinoma
Primary: Safety and Tolerability (Adverse Event Reported Per CTCAE v5) — 6; 0; 6; 6 Participants
Phase 1 N=20 Effect of Evobrutinib on Pharmacokinetics of a Combined Oral Contraceptive
Healthy
Primary: Area Under the Plasma Concentration-time Curve From Time Zero Extrapolated to Infinity (AUC0-inf) of Ethinyl Estradiol and Norethisterone — 1090; 36000 hour × picogram…
Phase 1 N=49 Pharmacokinetic and Safety Study of a 90 Day Intravaginal Ring Containing Tenofovir
HIV Infections
Primary: Measurement of TFV Levels in Plasma — 636.8; 1915.9; 3581.5; 5040.7 pg/mL
Phase 1 N=36 A TQT Study of Effect of M2951 on Cardiac Repolarization
Healthy
Primary: Placebo-corrected Change From Baseline in Corrected QT Interval by Fridericia' Formula (QTcF) for Evobrutinib — -1.62; -2.28 milliseconds
Phase 1 N=24 Pembrolizumab After Radiation Therapy in Treating Patients With Pleural Malignant Mesothelioma
Pleural Malignant Mesothelioma
Primary: Safety/Toxicity — 0; 0 participants
Phase 1 N=45 A Pilot Study to Assess Safety and Efficacy of SIR1-365 in Patients With Severe COVID-19
Corona Virus Infection
Primary: Number of Patients With Any TEAEs During the Treatment Period Baseline to Day 14 — 5; 10 Participants
Phase 1 N=87 A Study of LY3484356 in Women With Breast Cancer Before Having Surgery
Breast Cancer
Primary: Percent Change From Baseline in Estrogen Receptor (ER) Expression — -88.89; -81.50; -70.13 percent change
Phase 1 N=26 Safety, Tolerability, and Pharmacokinetics of Lumateperone in Pediatric Patients With Schizophrenia or Schizoaffective Disorder
Schizophrenia · Pediatric
Primary: Pharmacokinetics: Cmax — 19.12; 23.22 ng/mL
Phase 1 N=27 A Study of Imlunestrant (LY3484356) in Female Participants With Impaired Liver Function
Hepatic Insufficiency · Healthy
Primary: Pharmacokinetics (PK): Maximum Observed Concentration (Cmax) of Imlunestrant — 58.0; 74.9; 87.6; 46.2 nanograms per milliliter (ng/mL)
Phase 1 N=20 A Study of Imlunestrant (LY3484356) in Healthy Women
Healthy
Primary: Pharmacokinetics (PK): Area Under the Concentration Versus Time Curve From Zero to Infinity (AUC[0-∞]) of Midazolam — 12.3; 11.4 nanogram*hour per milliliter (ng*hr/mL)